NDC 50090-0610

COMBIVIR

Lamivudine And Zidovudine

COMBIVIR is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by A-s Medication Solutions. The primary component is Lamivudine; Zidovudine.

Product ID50090-0610_6bcd98d7-f0f8-4b4a-90c2-a9f5fbf030f8
NDC50090-0610
Product TypeHuman Prescription Drug
Proprietary NameCOMBIVIR
Generic NameLamivudine And Zidovudine
Dosage FormTablet, Film Coated
Route of AdministrationORAL
Marketing Start Date2010-10-19
Marketing CategoryNDA / NDA
Application NumberNDA020857
Labeler NameA-S Medication Solutions
Substance NameLAMIVUDINE; ZIDOVUDINE
Active Ingredient Strength150 mg/1; mg/1
Pharm ClassesHepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2019-12-31

Packaging

NDC 50090-0610-0

60 TABLET, FILM COATED in 1 BOTTLE (50090-0610-0)
Marketing Start Date2014-11-28
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 50090-0610-0 [50090061000]

COMBIVIR TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA020857
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2014-11-28
Marketing End Date2019-01-31

Drug Details

Active Ingredients

IngredientStrength
LAMIVUDINE150 mg/1

OpenFDA Data

SPL SET ID:653b7d4b-00fa-4156-b704-82123119445c
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 200082
  • 213088
  • Pharmacological Class

    • Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]
    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]

    NDC Crossover Matching brand name "COMBIVIR" or generic name "Lamivudine And Zidovudine"

    NDCBrand NameGeneric Name
    21695-846COMBIVIRlamivudine and zidovudine
    49702-202COMBIVIRlamivudine and zidovudine
    50090-0610COMBIVIRlamivudine and zidovudine
    52959-546COMBIVIRlamivudine and zidovudine
    53808-0895COMBIVIRlamivudine and zidovudine
    21695-996Lamivudine and ZidovudineLamivudine and Zidovudine
    31722-506LAMIVUDINE and ZIDOVUDINELAMIVUDINE and ZIDOVUDINE
    31722-739Lamivudine and ZidovudineLamivudine and Zidovudine
    33342-003Lamivudine and ZidovudineLamivudine and Zidovudine
    42291-363Lamivudine and ZidovudineLamivudine and Zidovudine
    43063-346Lamivudine and ZidovudineLamivudine and Zidovudine
    43063-900lamiVUDine and ZIDOVUDINElamiVUDine and ZIDOVUDINE
    50090-3920LAMIVUDINE and ZIDOVUDINELAMIVUDINE and ZIDOVUDINE
    50268-456LAMIVUDINE and ZIDOVUDINELAMIVUDINE and ZIDOVUDINE
    50436-0597Lamivudine and ZidovudineLamivudine and Zidovudine
    54741-102Lamivudine and Zidovudinelamivudine and zidovudine
    55700-096Lamivudine and ZidovudineLamivudine and Zidovudine
    57297-284LAMIVUDINE AND ZIDOVUDINELAMIVUDINE AND ZIDOVUDINE
    63629-4872Lamivudine and ZidovudineLamivudine and Zidovudine
    64380-707Lamivudine and ZidovudineLamivudine and Zidovudine
    65862-036Lamivudine and ZidovudineLamivudine and Zidovudine
    65862-597Lamivudine and ZidovudineLamivudine and Zidovudine

    Trademark Results [COMBIVIR]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    COMBIVIR
    COMBIVIR
    75244811 2158546 Live/Registered
    VIIV HEALTHCARE COMPANY
    1997-02-20

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.